PMID- 27203439
OWN - NLM
STAT- MEDLINE
DCOM- 20170606
LR  - 20211204
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 24
IP  - 7
DP  - 2016 Aug
TI  - Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric 
      Antigen Receptors.
PG  - 1178-86
LID - 10.1038/mt.2016.106 [doi]
AB  - Chimeric antigen receptor (CAR) endows specificity to T-cells independent of 
      human leukocyte antigen (HLA). This enables one immunoreceptor to directly target 
      the same surface antigen on different subsets of tumor cells from multiple 
      HLA-disparate recipients. Most approaches manufacture individualized 
      CAR(+)T-cells from the recipient or HLA-compatible donor, which are revealing 
      promising clinical results. This is the impetus to broaden the number of patients 
      eligible to benefit from adoptive immunotherapy such as to infuse third-party 
      donor derived CAR(+)T-cells. This will overcome issues associated with (i) time 
      to manufacture T-cells, (ii) cost to generate one product for one patient, (iii) 
      inability to generate a product from lymphopenic patients or patient's immune 
      cells fail to complete the manufacturing process, and (iv) heterogeneity of 
      T-cell products produced for or from individual recipients. Establishing a 
      biobank of allogeneic genetically modified immune cells from healthy third-party 
      donors, which are cryopreserved and validated in advance of administration, will 
      facilitate the centralizing manufacturing and widespread distribution of 
      CAR(+)T-cells to multiple points-of-care in a timely manner. To achieve this, it 
      is necessary to engineer an effective strategy to avoid deleterious allogeneic 
      immune responses leading to toxicity and rejection. We review the strategies to 
      establish "off-the-shelf" donor-derived biobanks for human application of 
      CAR(+)T-cells as a drug.
FAU - Torikai, Hiroki
AU  - Torikai H
AD  - Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Cooper, Laurence Jn
AU  - Cooper LJ
AD  - Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
AD  - Ziopharm Oncology Inc., Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160516
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - Cell- and Tissue-Based Therapy
MH  - *Gene Expression
MH  - Genetic Therapy
MH  - Graft vs Host Disease/etiology/prevention & control
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects/methods
MH  - Neoplasms/immunology/therapy
MH  - Receptors, Antigen, T-Cell/*genetics/*immunology
MH  - *Recombinant Fusion Proteins
MH  - T-Lymphocytes/*immunology/*metabolism
MH  - *Translational Research, Biomedical
PMC - PMC5088751
EDAT- 2016/05/21 06:00
MHDA- 2017/06/07 06:00
PMCR- 2017/08/01
CRDT- 2016/05/21 06:00
PHST- 2016/03/03 00:00 [received]
PHST- 2016/04/28 00:00 [accepted]
PHST- 2016/05/21 06:00 [entrez]
PHST- 2016/05/21 06:00 [pubmed]
PHST- 2017/06/07 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - S1525-0016(16)30351-3 [pii]
AID - 10.1038/mt.2016.106 [doi]
PST - ppublish
SO  - Mol Ther. 2016 Aug;24(7):1178-86. doi: 10.1038/mt.2016.106. Epub 2016 May 16.